Fiche publication
Date publication
novembre 2024
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
Tous les auteurs :
Pilati C, Soulabaille A, Gallois C, Blons H, Cayre A, Sroussi M, Le Corre D, Mouillet-Richard S, Mulot C, Le Malicot K, Reynies A, Bachet JB, Borg C, Di Fiore F, Guimbaud R, Bennouna J, André T, Taieb J, Penault-Llorca F, Laurent-Puig P
Lien Pubmed
Résumé
ERBB2-pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. We compared molecular methods to the gold-standard for assessing ERBB2 status and determined the prognostic value of ERBB2 amplification, mutations, and expression using data from two phase III trials involving nearly 3,000 stage III CC patients.
Mots clés
ERBB2 expression, HER2 amplification, IHC/FISH, NGS score, RNAseq, stage III CC prognosis
Référence
Gastroenterology. 2024 11 27;:
